A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma (Q42647126)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Peter Hersey

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Jeffrey Sosman

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Steven O'Day

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Jon Richards

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Agop Bedikian

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Rene Gonzalez

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

William Sharfman

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Robert Weber

8

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Theodore Logan

9

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Manuela Buzoianu

10

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Luz Hammershaimb

11

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

John M Kirkwood

12

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Etaracizumab Melanoma Study Group

13

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

language of work or name

0 references

publication date

1 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1526-1534

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Vitronectin and its receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

The alpha v beta 3 integrin "vitronectin receptor"

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of alphav integrins during angiogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo therapy of malignant melanoma by means of antagonists of alphav integrins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24821

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24821

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42647126&oldid=1964423590"